Frédéric Chéreau
Chief Executive Officer at LOGICBIO THERAPEUTICS, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Georges Gemayel | M | 64 |
Syndexa Pharmaceuticals Corp.
Syndexa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Syndexa Pharmaceuticals Corp. developed novel medicines for the treatment and prevention of metabolic diseases. The company was founded in 2005 and was headquartered in Watertown, MA.
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 14 years |
Jonathan Quick | M | - | 5 years | |
Rodolphe Clerval | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 4 years |
Nancy Krueger | F | 56 | 10 years | |
Sean Christie | M | - | 3 years | |
Marie Payton | F | - | 5 years | |
Belinda Cowling | M | 45 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 8 years |
Claudia Mitchell | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 2 years |
Stephane van Rooijen | M | 55 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 8 years |
Olivier Danos | M | 66 |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 3 years |
Michael Franken | M | 59 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 3 years |
Gianluca Pirozzi | M | 47 | 5 years | |
Willem Broekaert | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | - |
Simon Jombart | M | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Janice Olson | F | - | 3 years | |
Chris Freitag | M | 58 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 6 years |
Leen Thielemans | M | 49 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 5 years |
Etienne Eisenmann | M | - |
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | - |
Benoit Barteau | M | 39 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 7 years |
Christophe Pilch | M | 59 |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Patricia Françon | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 3 years |
Nicole Brument | F | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | - |
Sven Loebrich | M | - | - | |
Amel Gacquere | M | 48 |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Jean-Thomas Vilquin | M | - |
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | 24 years |
Gwladys Ghienne | F | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Grace Lochhead | F | - | 3 years | |
Glen Frick | M | 57 | - | |
Bruno Montanari | M | 49 |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | - |
Piyush Sharma | M | - | 7 years | |
David E. White | M | - | - | |
Tom Wilton | M | - | - | |
Lisa Carey | F | - | 9 years | |
Seng Cheng | M | - | 1 years | |
Ruth Diazaraque | M | - | 1 years | |
Christophe Hotermans | M | - | 4 years | |
Sarah Marshall | F | - | 10 years | |
Nicola Heffron | F | 52 | 1 years | |
Alexandra Francois | F | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Jean-Frédéric Chibret | M | 49 |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | - |
Ludovic Begue | M | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Søren Tulstrup | M | 59 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | 12 years |
Raphaël Wisniewski | M | 54 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 6 years |
Philippe Monteyne | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | - |
Jacques Dupuis | M | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Jean Franchi | F | 57 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 3 years |
Rémi Droller | M | 48 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 8 years |
Thierry Laugel | M | 57 |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | - |
Henry Skinner | M | 60 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 4 years |
Marc Dunoyer | M | 71 | - | |
Daniel Maciejasz | M | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Christian Champire | M | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | 9 years |
Patrick Preaux | M | 68 |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Sandrine Kubiak | F | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Patryk Mikucki | M | 49 | - | |
Jean-Paul Clément | M | 65 |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Jean-François Campion | M | 53 |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Matthias Hebben | M | - | 5 years | |
Guillaume Blavier | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | - |
Chris Mirabelli | M | 69 |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | 7 years |
Marcio Scorsin | M | - |
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | 24 years |
Tamar Thompson | F | 50 | 5 years | |
Morgan Sanford | F | - | - | |
Sandrine Surfaro | F | - |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | - |
Todd Spalding | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Cecilia Jones | F | 49 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 8 years |
Mark A. Kay | M | 66 | 8 years | |
Bryan Yoon | M | 46 | 1 years | |
Richard A. Moscicki | M | 72 | 4 years | |
Michael Wyzga | M | 69 | 4 years | |
Sofia Ioannidou | M | 45 | 2 years | |
Howard Mayer | M | 62 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | 6 years |
Brian Luque | M | - | - | |
Thomas Luby | M | - |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | 3 years |
Adi Barzel | M | - | 4 years | |
Sandra E. Poole | F | 60 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 17 years |
John Blake | M | 47 | 3 years | |
Michael Halpin | M | 62 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 15 years |
Daniel O’Connell | M | 44 | 3 years | |
Kyle Chiang | M | 44 | 5 years | |
Andrea Paul | F | 43 | - | |
Erez Chimovits | M | 60 | 4 years | |
Tomer Kariv | M | 62 | 3 years | |
Leon E. Chen | M | 49 | 6 years | |
Matthias B. Jaffé | M | 50 | 3 years | |
Srini Akkaraju Akkaraju | M | 56 | 3 years | |
Richard F. Syron | M | 80 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Henry E. Blair | M | 80 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 26 years |
Cornelius McGillicuddy | M | 83 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Joshua Blacher | M | 52 | - | |
Marc Beer | M | 59 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 4 years |
Louis J. Arcudi | M | 63 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 5 years |
Steven Burke | M | 63 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Hervé Suquet | M | - |
Université Paris 1 Panthéon-Sorbonne
| 5 years |
Daphne Karydas | F | 49 | 2 years | |
Peter T. Traynor | M | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
J. Goater | M | 48 | 2 years | |
Marcy Graham | F | 57 | - | |
Mark Enyedy | M | 60 | 2 years | |
Susan R. Kahn | F | 67 | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 61 | 61.00% |
France | 40 | 40.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Frédéric Chéreau
- Personal Network